ULTRA-RARE CANCERLeukemiaWHO 5th Edition Classification

T-cell Prolymphocytic Leukemia (T-PLL)

Ultra-Rare Malignancy (< 1 case per 1,000,000 / year) • Clinical Staging, Genomic Targets & Vetted Specialists

A rare and typically aggressive mature T-cell leukaemia with a very high white cell count, enlarged spleen and liver, and frequent skin involvement. It is defined by rearrangement of TCL1A and near-universal ATM abnormalities.

Request Rare Cancer Tumor Board Find NCI Treatment CentersAsk Vani AI Navigator
Who It Affects

Older adults, median around 65; male predominance

Annual Incidence

Approximately 0.6 per million per year

Clinical Evidence Review

Last audited: 2026-08-13 against NCCN, ESMO, and WHO 5th ed. guidelines.

Clinical Presentation & Hallmark Symptoms

Presenting signs most frequently observed across clinical case series

Markedly raised lymphocyte count found on a blood test
Enlarged spleen causing early satiety and left-sided abdominal fullness
Enlarged liver and lymph nodes
Skin rash or infiltration, and pleural effusions
Fatigue, anaemia and low platelets

Genomic Profiling & Defining Molecular Lesions

Critical diagnostic fusions, somatic mutations, and therapeutic targets

Rare malignancies frequently depend on distinct oncogenic drivers rather than conventional environmental carcinogens. Comprehensive Next-Generation Sequencing (NGS comprehensive panel) and FISH/IHC are mandatory to establish the true diagnosis and screen for basket trial agents.

inv(14)(q11q32) or t(14;14) - TCL1AATM deletion/mutationJAK3/STAT5BMTCP1

Standard-of-Care Treatment Protocol

Frontline and multimodal strategies established under international consensus guidelines

1

Alemtuzumab (anti-CD52), the most effective single agent

Administered in specialized high-volume oncology programs with subspecialty pathology and organ-preservation protocols.

2

Combination with pentostatin or fludarabine-based chemotherapy in selected patients

Administered in specialized high-volume oncology programs with subspecialty pathology and organ-preservation protocols.

3

Allogeneic stem cell transplant for consolidation in fit responders

Administered in specialized high-volume oncology programs with subspecialty pathology and organ-preservation protocols.

4

Watchful waiting in the rare truly indolent presentation

Administered in specialized high-volume oncology programs with subspecialty pathology and organ-preservation protocols.

5

Clinical trial enrolment at first relapse

Administered in specialized high-volume oncology programs with subspecialty pathology and organ-preservation protocols.

Clinical Trial Advisory: For rare and ultra-rare malignancies, enrollment in an active clinical trial or expanded-access program is widely considered the preferred standard of care by ASCO and NCCN panels.

Prognosis & Disease Trajectory

Objective clinical outlook without false reassurance

Poor without transplant, with median survival historically 1-2 years. Alemtuzumab produces high response rates but responses are rarely durable without allogeneic transplant consolidation.

Note: Statistics reflect cohort averages. Individual outcomes depend heavily on performance status, resectability, biomarker expression, and timely access to specialized tertiary care.

Active Research, Biomarkers & Clinical Trials

Novel investigational agents, phase I/II trials, and international rare disease consortia

BCL2 inhibition (venetoclax) combined with JAK/STAT inhibitors, and targeting the ATM-deficient state, are the most promising directions; an international T-PLL consortium sets response criteria.

Need Help Matching to an Active Rare Cancer Trial?

ByOnco scans ClinicalTrials.gov, NCI trial networks, and institutional registries for open patient cohorts.

Request Trial Match
Expert Clinicians

Verified Specialists for T-cell Prolymphocytic Leukemia

Browse All Oncologists

Dr. Susan O'Brien

Hematologist

30+ yrs exp

UC Irvine (formerly MD Anderson)

Irvine, USA

HematologyCLL/T-PLLAlemtuzumab Trials
Vetted DirectoryConsult Specialist

Dr. Daryl Tan

Hematologist

20+ yrs exp

SGH

Singapore, Singapore

HematologyLeukemias/LymphomasT-PLL
Vetted DirectoryConsult Specialist

Dr. Hugues de Thé

Hematologist

35+ yrs exp

Hôpital Saint-Louis

Paris, France

HematologyT-cell LeukemiasT-PLL
Vetted DirectoryConsult Specialist

Dr. Lalit Kumar

Medical Oncologist

30+ yrs exp

AIIMS, New Delhi

New Delhi, India

Hematologic CancersRare LeukemiasT-PLL
Vetted DirectoryConsult Specialist
Hospital Network

Designated Cancer Centers with Dedicated Programs

Search All 72 NCI Centers

Memorial Sloan Kettering Cancer Center

NY

NCI-Designated Comprehensive Cancer Center

World-leading rare tumor board & pediatric solid tumor protocols

Proton TherapyCAR-T Cell TherapyRobotic Surgery
1,000+ Active Clinical TrialsView Center Profile

University of Texas MD Anderson Cancer Center

TX

NCI-Designated Comprehensive Cancer Center

Largest specialized rare cancer and sarcoma multidisciplinary program

Proton TherapyCAR-T Cell TherapyCyberKnife SBRT
1,200+ Active Clinical TrialsView Center Profile

Dana-Farber / Harvard Cancer Center

MA

NCI-Designated Comprehensive Cancer Center

Pioneering genomic molecular tumor boards & rare histologies

Proton TherapyCAR-T Cell TherapyPhase I Unit
1,100+ Active Clinical TrialsView Center Profile

Mayo Clinic Comprehensive Cancer Center

MN

NCI-Designated Comprehensive Cancer Center

High-volume surgical oncology & rare endocrine/neuroendocrine expertise

Proton TherapyCAR-T Cell TherapyCyberKnife SBRT
600+ Active Clinical TrialsView Center Profile

Frequently Asked Clinical Questions

Authoritative guidance on diagnosis, tumor boards, genomic markers, and care options

Related Rare Malignancies in Catalog

ultra-rare

Malignant Rhabdoid Tumor

ultra-rare

Hepatosplenic T-cell Lymphoma (HSTCL)

ultra-rare

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

ultra-rare

Erdheim-Chester Disease (ECD)

Independent Tumor Board Review

Facing a Diagnosis of T-cell Prolymphocytic Leukemia?

Rare cancers demand rare expertise. Connect your medical records to US NCI-fellowship trained oncologists, subspecialist pathologists, and active clinical trial investigators within 12 to 72 hours.

Upload Scans for Second Opinion Schedule Virtual Teleconsult